MRI to Guide Biopsy Decisions in Prostate Cancer Screening

Use of MRI led to fewer biopsies and fewer diagnoses of clinically insignificant cancer.

Increasingly, magnetic resonance imaging (MRI) is being incorporated into prostate cancer screening; the ultimate goal is fewer biopsies and less overdiagnosis. In this Swedish trial, 13,000 middle-aged men (age range, 50–60) who had prostate-specific antigen (PSA) screening tests were randomized into two groups, as follows:

In the “MRI-targeted biopsy” group, patients with elevated PSA levels (3–10 ng/mL) underwent MRI, and suspicious lesions were biopsied; no biopsies were done if MRI showed no lesions.
In the “systematic biopsy” group, patients with elevated PSA also underwent MRI, but these patients had standard systematic biopsies (10–12 cores) plus biopsies of suspicious lesions identified on MRI.

Patients who had no biopsies or negative…

Reviewing Author

Allan S. Brett, MD

Disclosures

Nothing to disclose

Allan S. Brett, MD

Disclosures

Nothing to disclose

MRI to Guide Biopsy Decisions in Prostate Cancer Screening

Topics

Reviewing Author